Acute myeloid leukemia (AML) remains one of the most aggressive forms of cancer, solid or liquid, stalling at 25% survival at 5 years in adults. The scientific community now recognizes that multiple different tumoral cell populations are present simultaneously at diagnosis and throughout disease evolution. This has raised new challenges in how to tackle these diseases. Thus, new diagnostic tools are required in order to adequately characterize these multiple populations. In our lab, we are developing such a novel approach, namely an Interconnected Robotic Imaging and Single-cell RNA-sequencing (IRIS) platform that aims to provide different data types simultaneously for individual cells. By coupling imaging and gene sequencing data we aim to uncover new morphological biomarkers that may be specific to certain genetic profiles. This, in turn, may potentiate the discovery of de novo markers as well as reducing the times from diagnosis to treatment.